Standard

Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. / van der Aar, Angelic M. G.; Sibiryak, Darya S.; Bakdash, Ghaith et al.

In: Journal of allergy and clinical immunology, Vol. 127, No. 6, 2011, p. 1532-U334.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

van der Aar, AMG, Sibiryak, DS, Bakdash, G, van Capel, TMM, van der Kleij, HPM, Opstelten, D-JE, Teunissen, MBM, Kapsenberg, ML & de Jong, EC 2011, 'Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells', Journal of allergy and clinical immunology, vol. 127, no. 6, pp. 1532-U334. https://doi.org/10.1016/j.jaci.2011.01.068

APA

van der Aar, A. M. G., Sibiryak, D. S., Bakdash, G., van Capel, T. M. M., van der Kleij, H. P. M., Opstelten, D-J. E., Teunissen, M. B. M., Kapsenberg, M. L., & de Jong, E. C. (2011). Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. Journal of allergy and clinical immunology, 127(6), 1532-U334. https://doi.org/10.1016/j.jaci.2011.01.068

Vancouver

van der Aar AMG, Sibiryak DS, Bakdash G, van Capel TMM, van der Kleij HPM, Opstelten D-JE et al. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. Journal of allergy and clinical immunology. 2011;127(6):1532-U334. doi: 10.1016/j.jaci.2011.01.068

Author

van der Aar, Angelic M. G. ; Sibiryak, Darya S. ; Bakdash, Ghaith et al. / Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. In: Journal of allergy and clinical immunology. 2011 ; Vol. 127, No. 6. pp. 1532-U334.

BibTeX

@article{aa687fd0c2a84aa5a3b573a40cfc441f,
title = "Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells",
abstract = "Background: The vitamin D metabolite 1,25(OH) 2D3 (VitD3) is a potent immunosuppressive drug and, among others, is used for topical treatment of psoriasis. A proposed mechanism of VitD3-mediated suppression is priming of dendritic cells (DCs) to induce regulatory T (Treg) cells. Objective: Currently, there is confusion about the phenotype of VitD3-induced Treg cells and the DC-derived molecules driving their development. We investigated Treg cell induction after VitD3 priming of 2 distinct skin DC subsets: Langerhans cells (LCs) and dermal dendritic cells (DDCs). Methods: LCs and DDCs primed with VitD3 were cocultured with allogeneic naive T cells. The phenotype and function of the DCs and induced T cells were analyzed. Results: Both VitD3-primed DC subtypes induced T cells with regulatory activity. Unexpectedly, whereas the Treg cell populations generated by VitD3-primed LCs were CD25(hi) CD127(lo) forkhead box protein 3 (Foxp3)-positive cells, which meet the criteria of classical inducible Treg cells, the T cells developing in response to VitD3-primed DDCs were Foxp3(-) T(R)1 cells expressing IL-10. Inhibition experiments revealed that LC-derived TGF-beta is a key factor in the induction of Foxp3 1 Treg cells, whereas DDC-derived IL-10 is important for the induction of IL-10(+) T(R)1 cells. Conclusion: Thus we report the novel finding that distinct but closely related DC subsets are differentially programmed by VitD3 to support development of either TGF-beta-dependent Foxp3(+) Treg cells or IL-10-dependent IL-10(+) Treg cells. (J Allergy Clin Immunol 2011;127:1532-40.)",
author = "{van der Aar}, {Angelic M. G.} and Sibiryak, {Darya S.} and Ghaith Bakdash and {van Capel}, {Toni M. M.} and {van der Kleij}, {Hanneke P. M.} and Opstelten, {Dirk-Jan E.} and Teunissen, {Marcel B. M.} and Kapsenberg, {Martien L.} and {de Jong}, {Esther C.}",
year = "2011",
doi = "10.1016/j.jaci.2011.01.068",
language = "English",
volume = "127",
pages = "1532--U334",
journal = "Journal of allergy and clinical immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells

AU - van der Aar, Angelic M. G.

AU - Sibiryak, Darya S.

AU - Bakdash, Ghaith

AU - van Capel, Toni M. M.

AU - van der Kleij, Hanneke P. M.

AU - Opstelten, Dirk-Jan E.

AU - Teunissen, Marcel B. M.

AU - Kapsenberg, Martien L.

AU - de Jong, Esther C.

PY - 2011

Y1 - 2011

N2 - Background: The vitamin D metabolite 1,25(OH) 2D3 (VitD3) is a potent immunosuppressive drug and, among others, is used for topical treatment of psoriasis. A proposed mechanism of VitD3-mediated suppression is priming of dendritic cells (DCs) to induce regulatory T (Treg) cells. Objective: Currently, there is confusion about the phenotype of VitD3-induced Treg cells and the DC-derived molecules driving their development. We investigated Treg cell induction after VitD3 priming of 2 distinct skin DC subsets: Langerhans cells (LCs) and dermal dendritic cells (DDCs). Methods: LCs and DDCs primed with VitD3 were cocultured with allogeneic naive T cells. The phenotype and function of the DCs and induced T cells were analyzed. Results: Both VitD3-primed DC subtypes induced T cells with regulatory activity. Unexpectedly, whereas the Treg cell populations generated by VitD3-primed LCs were CD25(hi) CD127(lo) forkhead box protein 3 (Foxp3)-positive cells, which meet the criteria of classical inducible Treg cells, the T cells developing in response to VitD3-primed DDCs were Foxp3(-) T(R)1 cells expressing IL-10. Inhibition experiments revealed that LC-derived TGF-beta is a key factor in the induction of Foxp3 1 Treg cells, whereas DDC-derived IL-10 is important for the induction of IL-10(+) T(R)1 cells. Conclusion: Thus we report the novel finding that distinct but closely related DC subsets are differentially programmed by VitD3 to support development of either TGF-beta-dependent Foxp3(+) Treg cells or IL-10-dependent IL-10(+) Treg cells. (J Allergy Clin Immunol 2011;127:1532-40.)

AB - Background: The vitamin D metabolite 1,25(OH) 2D3 (VitD3) is a potent immunosuppressive drug and, among others, is used for topical treatment of psoriasis. A proposed mechanism of VitD3-mediated suppression is priming of dendritic cells (DCs) to induce regulatory T (Treg) cells. Objective: Currently, there is confusion about the phenotype of VitD3-induced Treg cells and the DC-derived molecules driving their development. We investigated Treg cell induction after VitD3 priming of 2 distinct skin DC subsets: Langerhans cells (LCs) and dermal dendritic cells (DDCs). Methods: LCs and DDCs primed with VitD3 were cocultured with allogeneic naive T cells. The phenotype and function of the DCs and induced T cells were analyzed. Results: Both VitD3-primed DC subtypes induced T cells with regulatory activity. Unexpectedly, whereas the Treg cell populations generated by VitD3-primed LCs were CD25(hi) CD127(lo) forkhead box protein 3 (Foxp3)-positive cells, which meet the criteria of classical inducible Treg cells, the T cells developing in response to VitD3-primed DDCs were Foxp3(-) T(R)1 cells expressing IL-10. Inhibition experiments revealed that LC-derived TGF-beta is a key factor in the induction of Foxp3 1 Treg cells, whereas DDC-derived IL-10 is important for the induction of IL-10(+) T(R)1 cells. Conclusion: Thus we report the novel finding that distinct but closely related DC subsets are differentially programmed by VitD3 to support development of either TGF-beta-dependent Foxp3(+) Treg cells or IL-10-dependent IL-10(+) Treg cells. (J Allergy Clin Immunol 2011;127:1532-40.)

U2 - 10.1016/j.jaci.2011.01.068

DO - 10.1016/j.jaci.2011.01.068

M3 - Article

C2 - 21497886

VL - 127

SP - 1532-U334

JO - Journal of allergy and clinical immunology

JF - Journal of allergy and clinical immunology

SN - 0091-6749

IS - 6

ER -

ID: 1419418